HSA and FSA Rules for Compounded GLP-1s: What Actually Qualifies

If you have a Health Savings Account (HSA) or Flexible Spending Account (FSA), you already know these accounts let you pay for qualified medical expenses with pre-tax dollars. The question is whether compounded GLP-1 medications — semaglutide or tirzepatide prepared by a compounding pharmacy — qualify as eligible expenses. The answer is usually yes, but the specifics matter.

The Basic Rule

IRS Publication 502 defines qualified medical expenses for HSA and FSA purposes. Prescription medications are explicitly included, provided they require a prescription from a licensed healthcare provider. Compounded medications that are prepared pursuant to a valid prescription by a licensed pharmacy meet this definition.

The key requirement is not whether the medication is FDA-approved — it's whether it was prescribed by a licensed provider and dispensed by a licensed pharmacy. Since compounded GLP-1s require both a prescription and a pharmacy license, they satisfy the basic IRS criteria for qualified medical expenses.

The Medical Necessity Layer

HSA and FSA reimbursement for prescription medications also requires that the medication be used to treat, diagnose, cure, or prevent a medical condition. Weight loss medications prescribed for cosmetic purposes alone are generally not eligible.

For GLP-1 medications, the medical necessity requirement is typically straightforward to meet because these drugs are prescribed for diagnosed conditions:

• Obesity (BMI ≥ 30): A diagnosed medical condition recognized by the IRS as a disease.
• Overweight with comorbidities (BMI ≥ 27): When prescribed in conjunction with a diagnosis of type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or other weight-related conditions.
• Type 2 diabetes: The original approved indication for semaglutide (Ozempic) and tirzepatide (Mounjaro).

The IRS recognized obesity as a disease for tax-deduction purposes in Revenue Ruling 2002-19. This ruling established that expenses for the treatment of obesity — including prescription medications — qualify as medical expenses for both itemized deduction and HSA/FSA purposes.

HSA vs. FSA: Practical Differences

Health Savings Account (HSA)

HSAs are paired with high-deductible health plans (HDHPs) and the money is yours — it rolls over year to year and follows you if you change employers. For compounded GLP-1s, you can pay the pharmacy directly with your HSA debit card, or pay out-of-pocket and reimburse yourself from the HSA later. HSAs have no "use it or lose it" deadline, so timing isn't a concern.

The 2026 HSA contribution limits are $4,300 for individual coverage and $8,550 for family coverage (with an additional $1,000 catch-up for those 55 and older). At $200-400/month for compounded semaglutide, a year of treatment represents $2,400-4,800 — a significant portion of the annual contribution limit but within the range that many families can fund through payroll deductions.

Flexible Spending Account (FSA)

FSAs are employer-sponsored accounts funded through pre-tax payroll deductions. The key difference from HSAs is the "use it or lose it" rule — most FSA funds must be used within the plan year (some employers allow a $640 rollover or a 2.5-month grace period). If you're planning to use an FSA for compounded GLP-1s, you need to estimate your annual medication costs during open enrollment and set your contribution accordingly.

The 2026 FSA contribution limit is $3,300 for healthcare FSAs. This means that FSA funds alone may not cover a full year of compounded GLP-1 treatment if your monthly cost exceeds approximately $275. Plan accordingly — you can always supplement FSA funds with out-of-pocket payments for amounts exceeding your FSA balance.

What the Pharmacy Receipt Needs to Show

Most HSA/FSA administrators will process a claim for a compounded prescription if the receipt includes:

• The patient's name
• The pharmacy name and license information
• The date of service
• The medication name (e.g., "compounded semaglutide injection")
• The amount charged
• An indication that a prescription was required (Rx number)

If your telehealth provider bundles the prescription, consultation, and medication into a single charge (which many do), the receipt may not itemize the medication separately. In that case, you may need to request an itemized receipt from the provider that breaks out the medication cost, or ask for a superbill showing the diagnosis code and treatment provided.

When Claims Get Denied (and How to Appeal)

Denial typically occurs for one of three reasons:

• Missing documentation: The administrator cannot verify that the expense was a prescription medication for a qualifying condition. Solution: provide a Letter of Medical Necessity from your prescriber plus the pharmacy receipt.
• Cosmetic classification: The administrator classifies the weight loss medication as cosmetic rather than medical. Solution: provide documentation of your diagnosed medical condition (obesity, diabetes, etc.) and a letter from your prescriber explaining the medical necessity.
• Bundled charges: The administrator cannot distinguish the medication cost from the consultation fee in a bundled charge. Solution: request an itemized receipt from the provider.

Most denials can be overturned on appeal with proper documentation. The key is establishing that the medication was prescribed for a diagnosed medical condition — not requested by the patient for weight management alone.

The Tax Advantage in Real Numbers

Using pre-tax HSA/FSA dollars to pay for compounded GLP-1s effectively reduces your cost by your marginal tax rate. If your combined federal and state marginal tax rate is 30%, a $200/month compounded semaglutide prescription costs you $140/month in after-tax dollars when paid through an HSA or FSA. Over a year, that's $720 in tax savings — real money that partially offsets the out-of-pocket cost of compounded medications.

Providers With HSA/FSA-Compatible Receipts